Unity Biotechnology, Inc.
NASDAQ:UBX
1.26 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Unity Biotechnology, Inc. |
Symbool | UBX |
Munteenheid | USD |
Prijs | 1.26 |
Beurswaarde | 21,227,976 |
Dividendpercentage | 0% |
52-weken bereik | 1.22 - 2.26 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Anirvan Ghosh Ph.D. |
Website | https://unitybiotechnology.com |
An error occurred while fetching data.
Over Unity Biotechnology, Inc.
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)